What's Happening?
The UK's National Institute for Health and Care Excellence (NICE) has updated its cost-effectiveness threshold for appraising new medicines, raising it from £20,000-£30,000 to £25,000-£35,000 per quality adjusted life year (QALY) gained. This change aims
to support access to innovative medicines, particularly for rare diseases. The update is expected to enable more medicines to be recommended each year, improving patient access to new treatment options. However, challenges remain for rare disease therapies, which often require higher investment and face difficulties in meeting standard cost-effectiveness criteria.
Why It's Important?
The update to NICE's cost-effectiveness threshold is a significant step towards improving access to innovative treatments, particularly for rare diseases. It reflects a growing recognition of the value of modern medicines and the need for more flexible appraisal processes. This change could enhance the UK's attractiveness for pharmaceutical investment and clinical trials, boosting the country's position in global healthcare innovation. However, further reforms are needed to address the unique challenges of rare disease treatments, ensuring equitable access and supporting the development of therapies for underserved patient populations.
